Stem Cell Mitochondria Repair Leaky Lung Blood Vessels in Preclinical ARDS Models

Why it matters: ARDS is a life-threatening form of respiratory failure in which inflammation breaks down the barrier between the lung's air spaces and its blood vessels. Fluid floods the alveoli, causing hypoxemia and systemic inflammation. No drug directly repairs this barrier. Pulmonary endothelial cells are central to the leak, and earlier work, including from this group, links their hyperpermeability to mitochondrial depolarization and dysfunction. Observational data in septic patients also tie mitochondrial dysfunction to higher mortality. Mesenchymal stromal cells (MSC) are known to donate mitochondria to injured cells through tunnelling nanotubes or extracellular vesicles, which prompted the idea of transplanting isolated MSC mitochondria directly.

What was studied: The team isolated mitochondria from human bone-marrow MSC (ATCC, passages 4-6) with a density-centrifugation kit and used them immediately. They transplanted the mitochondria into primary human pulmonary microvascular endothelial cells (HPMEC) challenged with E. coli lipopolysaccharide (LPS) or with plasma from ARDS patients. The patient plasma came from both the hypo-inflammatory and hyper-inflammatory phenotypes, which differ in biomarkers, outcomes and treatment response. After 24 hours they assessed mitochondrial function, inflammatory status and endothelial barrier integrity. THP-1 macrophage-like cells were also used in the experimental work. In vivo, LPS-challenged mice received MSC mitochondria intravenously, and lung injury severity and inflammatory response were evaluated.

Key results: Both LPS and ARDS plasma produced endothelial hyperpermeability together with mitochondrial dysfunction. HPMEC readily internalized the MSC mitochondria, and the authors report no cytotoxicity and no inflammatory response to the transplant. Transplantation mitigated the mitochondrial dysfunction and restored barrier integrity in the challenged cells. In mice, MSC mitochondria alleviated lung injury and reduced inflammatory cell infiltration into the alveoli. They also increased VE-cadherin mRNA in lung tissue. VE-cadherin is a key endothelial junction protein, so this suggests the alveolar-capillary barrier was restored.

Implications: The findings support mitochondrial transplantation as a potential cell-free approach to endothelial dysfunction in acute inflammation. Because it worked against plasma from both ARDS subphenotypes, the effect may not depend on one inflammatory profile. Isolated mitochondria also avoid some safety and logistical concerns of whole-cell therapy, although this study did not test that directly. The authors conclude that further exploration in ARDS is warranted.

Caveats: This is entirely preclinical. The work used cultured cells and an LPS mouse model, which only partly reproduces human ARDS. The text available for this summary did not include detailed quantitative results, dosing, durability of benefit or mechanisms of mitochondrial uptake and integration. Manufacturing, storage and delivery of isolated mitochondria at clinical scale remain unresolved. Human safety and efficacy are unknown.